Important Notice from CHUGAI PHARMACEUTICAL

PICKUP CONTENTS

Chugai Pharmaceutical 100th Anniversary Site

We look back at Chugai's 100 years of contributing to patients and society through numerous innovations since its founding in 1925.

History of Chugai Pharmaceutical

Our founding spirit in 1925 was to "make drugs that benefit society."
Even after 100 years have passed, our founding commitment to "for patients" remains unchanged.

Advanced and sustainable patient-centric healthcare

Learn about Chugai's core values, which prioritize each patient’s wellbeing as our highest consideration in conducting our business.

ABOUT

We get to the future ahead of the disease.

Share of therapeutic antibody sales in Japan*1

No.1

Breakthrough Therapy Designations*2

9times

Innovative new drugs
as a percentage of sales*3

65%

Countries approving Chugai products

More than110

Operating profit growth after starting the strategic alliance with Roche (2002-2024)

21times higher

Chugai is a research and development-oriented pharmaceutical company with unique technology and science as its strengths. In collaboration with Roche, we are committed to continuously generating innovation with the aim of continuously providing patients with innovative drugs and services.

For those who want to know about
Chugai's characteristics and strengths
What kind of company is Chugai Pharmaceutical?
For those who want to know more about
Chugai
About Chugai

  • *1 Copyright © 2024 IQVIA. Calculated based on JPM 2023.Reprinted with permission. The scope of the market is defined by Chugai.

  • *2 A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms.

  • *3 Proportion of sales from products that qualify for premium pricing.

The three key drivers driving Chugai's growth are RED* Shift, DX, and open innovation.
We will shift our resources to discovery
research and early clinical development, which are the source of our value creation, apply digital technology to create innovative new drugs and increase efficiency in the value chain, and actively collaborate with external partners.

* Research and Early Development

The purpose of innovation, R&D efforts, and results

Innovation

SUSTAINABILITY

Putting sustainability at the heart of our business
Creating shared value with Society and developing together

We aim to lead solving social issues through our business activities, share the value created through these activities with our diverse stakeholders, and to grow together with society.

Chugai's Perspective on Social Issues and How to Solve Them

We aim to lead solving social issues through our business activities, share the value created through these activities with our diverse stakeholders, and to grow together with society.

Chugai's Perspective on Social Issues and How to Solve Them

The Fujieda Plant has received the Director-General of the Kanto Bureau of Economy, Trade, and Industry Award for Excellent Energy Management Businesses for FY 2024

  • Global Environment

The 5th Workshop on Multidisciplinary Team Care for Healthcare Professionals in Cambodia

  • Sustainable Patient-Centric Healthcare
  • Global Health
  • Healthcare

2024 Contribution of Para-transit Vehicles to Welfare Services

  • Social Contribution
  • Social Welfare

Chugai Presents Nationwide Wheelchair Softball Experience Event

  • Social Contribution
  • Inclusive Society
  • Para-Sports

Donation of 'Roche Children's Walk 2024' funds to Social Welfare Corporation Hokushin Fukushikai Asunaro Gakuen

  • Social Contribution
  • Social Welfare
  • Local Communities

Support for a remote ophthalmology screening project in Cambodia

  • Sustainable Patient-Centric Healthcare
  • Global Health
  • Social Contribution
  • Healthcare

Contributing to Global Environmental ProtectionEfforts to Protect Water Resources at Our Production Sites, 2024

  • Social Contribution
  • Local Communities
  • Global Environment

Sales of Products to Support Recovery from the 2024 Noto Peninsula Earthquake

  • Social Contribution
  • Local Communities

View all Chugai activity reports

Activity Reports

Stories

Creating Continuous Innovation.
The Story of Our Challenges

  • #Sustainability
  • #Co-Creation

The Bio Lab’s Development of the Next Generation of Scientists

One of Chugai Pharmaceutical’s research centers is the Chugai Life Science Park Yokohama in Totsuka-ku, Yokohama City. Within this center is the BIO LAB,

  • Sustainability
  • Social Contribution
  • Bio Lab
  • #Sustainability

Corporate Growth Through Employee Health: Health and Productivity Management Alongside Employees to Create Platforms for Innovation and Working Environments for Peace of Mind

Chugai Pharmaceutical contributes to the health of people across the world through its innovative pharmaceuticals and services. Essential to fulfilling this mi

  • Sustainability
  • Human Resources
  • Health and Productivity Management
  • #Sustainability

There Is No Point in Producing Medicine in a World in Which People Cannot Live - Chugai’s Approach to Global Environmental Protection

The Chugai Pharmaceutical Group considers global environmental protection to be an important foundation for all its business activities, and has set three them

  • Global Environment
  • Supply Chain Management
  • #Patient-Centricity
  • #Sustainability
  • #Co-Creation

Working with Patients to Create a Future in Which Every Person Can Choose the Optimal Form of Treatment

Patients are at the center of all Chugai Pharmaceutical’s corporate activities, and the company is in constant pursuit of value to benefit them. Takeuchi

  • Sustainable Healthcare
  • PHARMONY
  • #Patient-Centricity
  • #Digital Technology

Realizing patient-centric clinical trials with DX. Decentralized clinical trials (DCT) initiative to achieve patient-centricity and more efficient clinical studies simultaneously

 “We want to create a society that enables the choice of clinical trial methods that are closer to patients. The realization of DCT is expected to l

  • R&D
  • DX
  • Clinical Trials
  • #Digital Technology
  • #Open Innovation
  • #Co-Creation

Accelerating DX with open innovation. The future of healthcare aimed for through company-wide awareness reform

Yanaizu belongs to the Digital Strategy Department which leads Chugai Pharmaceutical’s digital transformation (DX). Since joining the company in 2023, sh

  • R&D
  • DX
  • Partnering
  • CHUGAI DIGITAL VISION 2030
  • #Sustainability
  • #Co-Creation

Chugai Pharmaceutical aims to realize a society in which everyone can shine, whether or not they have a disability

Chugai Pharmaceutical aims to foster an inclusive organizational culture in which individual employees make the most of their abilities and diverse employees r

  • Recruitment
  • Human Resources
  • Diversity
  • #Co-Creation

Contributing to patients through drug discovery – Leveraging diverse individuals to achieve results

Rie Sugai, Group Manager, API Process Development Dept., Early Stage Cell Culture Process Development Group

  • Human Resources
  • Enable excellence of individuals

Our employees want to bring happiness to our patients. Here are the thoughts of these employees and the stories of their challenges.

Read Chugai's culture

Stories

UPDATE

Latest Information

Notices What's new News

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.